414 related articles for article (PubMed ID: 29979237)
1. Prognostic markers in clinical stage I seminoma and nonseminomatous germ cell tumours.
Pedraza AM; Stephenson AJ
Curr Opin Urol; 2018 Sep; 28(5):448-453. PubMed ID: 29979237
[TBL] [Abstract][Full Text] [Related]
2. [Management of localized germ-cell tumours of the testis].
Loriot Y; Fizazi K
Rev Prat; 2007 Feb; 57(4):379-84. PubMed ID: 17455739
[TBL] [Abstract][Full Text] [Related]
3. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
4. Management of stage I testicular germ cell tumours.
Chovanec M; Hanna N; Cary KC; Einhorn L; Albany C
Nat Rev Urol; 2016 Nov; 13(11):663-673. PubMed ID: 27618772
[TBL] [Abstract][Full Text] [Related]
5. Surveillance or adjuvant treatments in stage 1 testis germ-cell tumours.
Cullen M
Ann Oncol; 2012 Sep; 23 Suppl 10():x342-8. PubMed ID: 22987989
[TBL] [Abstract][Full Text] [Related]
6. Management of Low-Stage Testicular Seminoma.
Pearce SM; Liauw SL; Eggener SE
Urol Clin North Am; 2015 Aug; 42(3):287-98. PubMed ID: 26216816
[TBL] [Abstract][Full Text] [Related]
7. Management of clinical stage I testicular pure seminoma. Report on 42 patients and review of the literature.
Porcaro AB; Antoniolli SZ; Schiavone D; Maffei N; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):77-80. PubMed ID: 12161941
[TBL] [Abstract][Full Text] [Related]
8. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.
Oldenburg J; Aparicio J; Beyer J; Cohn-Cedermark G; Cullen M; Gilligan T; De Giorgi U; De Santis M; de Wit R; Fosså SD; Germà-Lluch JR; Gillessen S; Haugnes HS; Honecker F; Horwich A; Lorch A; Ondruš D; Rosti G; Stephenson AJ; Tandstad T
Ann Oncol; 2015 May; 26(5):833-838. PubMed ID: 25378299
[TBL] [Abstract][Full Text] [Related]
9. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of testicular germ cell tumors in patients aged 50 years and older: A large-scale study from the Cancer Registration Committee of the Japanese Urological Association.
Kawai T; Tanaka Y;
Int J Urol; 2017 Feb; 24(2):124-128. PubMed ID: 27915468
[TBL] [Abstract][Full Text] [Related]
11. The approach to the patient with synchronous bilateral germ cell tumors: a lesson in oncologic prioritization.
Feldman DR
Oncology (Williston Park); 2010 Jul; 24(8):761-3. PubMed ID: 20718258
[No Abstract] [Full Text] [Related]
12. The clinical features and management of testicular germ cell tumours in patients aged 60 years and older.
Wheater MJ; Manners J; Nolan L; Simmonds PD; Hayes MC; Mead GM
BJU Int; 2011 Dec; 108(11):1794-9. PubMed ID: 21627751
[TBL] [Abstract][Full Text] [Related]
13. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis.
Amato RJ; Ro JY; Ayala AG; Swanson DA
Urology; 2004 Jan; 63(1):144-8; discussion 148-9. PubMed ID: 14751368
[TBL] [Abstract][Full Text] [Related]
14. Treatment in germ cell tumours: state of the art.
Tjan-Heijnen VC; Oosterhof GO; de Wit R; De Mulder PH
Eur J Surg Oncol; 1997 Apr; 23(2):110-7. PubMed ID: 9158183
[TBL] [Abstract][Full Text] [Related]
15. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
16. Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group.
Aparicio J; García Del Muro X; Maroto P; Terrasa J; Castellano D; Bastús R; Gumà J; Sagastibeltza N; Durán I; Ochenduszko S; Meana JA; García-Sánchez J; Arranz JA; Gironés R; Germà JR
Clin Transl Oncol; 2021 Jan; 23(1):58-64. PubMed ID: 32462393
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
18. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
19. Conditional risk of relapse in patients with germ cell testicular tumors: personalizing surveillance in clinical stage 1 disease.
Goldberg H; Madhur N; Hamilton RJ
Curr Opin Urol; 2018 Sep; 28(5):454-460. PubMed ID: 29916845
[TBL] [Abstract][Full Text] [Related]
20. Exploration of treatment options for the management of stage I testicular seminoma.
Bernal F; Raman JD
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1081-90. PubMed ID: 18588453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
